Introduction
The Raf proteins are highly conserved serine ± threonine protein kinases that are integral members of intracellular signalling cascades. In mammals, the Raf family comprises three members, A-Raf, B-Raf and Raf-1, that share a high degree of sequence similarity (Daum et al., 1994) . The N-terminal part of the proteins comprises the regulatory domain that binds essential cofactors while the C-terminal domain comprises the catalytic kinase domain. All three kinases are known to bind Ras.GTPases and all three are translocated to the plasma membrane by oncogenic Ras (Marais et al., 1997) . All three proteins bind to MEK and can phosphorylate MEK in immunecomplex kinase assays (Pritchard et al., 1996; Marais et al., 1997; HuÈ ser et al., 2001) . All three genes are ubiquitously expressed although their expression levels vary enormously between dierent tissues (Storm et al., 1990; Barnier et al., 1995; Luckett et al., 2000) . The best characterized signalling cascade involving the Raf proteins is the Ras/Raf/MEK/ERK cascade which is activated by a wide variety of activated cell surface receptors. The function of activated Raf proteins in this cascade appears to be to provide a signalling link between Ras and ERKs by activating MEK, the upstream activator of the ERKs. ERKs have multiple targets in the cell and allow the cell to respond appropriately to proliferative, apoptotic and dierentiation signals. This cascade is also involved in mediating some of the transforming eects of activated oncogenes and inhibition studies using dominant negative and antisense constructs have shown that Raf proteins are required for transformation by v-Haras and v-src (Kolch et al., 1991; Qureshi et al., 1993) .
Immunoprecipitated Raf proteins dier widely in their ability to activate MEK/ERK as measured by the kinase cascade assay (Pritchard et al., 1995; Marais et al., 1997) . B-Raf immunoprecipitated from growth factor-stimulated mouse embryonic ®broblasts (MEFs) is the strongest activator of MEK/ERK even though it is expressed at extremely low levels in this cell type (HuÈ ser et al., 2001) . By contrast, A-Raf immunoprecipitated from the same cells does not measurably activate MEK/ERK (HuÈ ser et al., 2001 ) and A-Raf activity towards MEK have so far only been detected in primary rat ventricular myocytes stimulated with powerful hypertrophic agonists (Bogoyevitch et al., 1995) . Raf-1 immunoprecipitated from growth factor-stimulated MEFs also has extremely low activity towards MEK/ ERK compared to B-Raf (HuÈ ser et al., 2001) . On the basis of these dierential activities it has been suggested that the Raf proteins may determine whether a cell undergoes cell cycle progression or arrest in response to an extracellular stimulus, by controlling the level of ERK activation (Woods et al., 1997) .
Despite the well established role of the Raf proteins in MEK/ERK activation, other functions for the Raf proteins have been proposed (Hagemann and Rapp, 1999) . Besides MEK and Ras, A-Raf has also been shown to bind to the b subunit of CK2 (Hagemann et al., 1997) and to pyruvate kinase M2 (M2-PK). A recent study showed that A-Raf interacts with hTOM and hTIM, two proteins involved in the mitochondrial transport system, leading to the discovery that A-Raf is located exclusively in mitochondria (Yuryev et al., 2000) . Recently, we (HuÈ ser et al., 2001 ) and others (Mikula et al., 2001 ) provided evidence that the major function of Raf-1 is in preventing apoptosis and that this function may be independent of any eect on ERK. MEFs derived from raf-1 7/7 mice demonstrated increased programmed cell death (PCD) in response to several apoptotic stimuli, but ERK activation was not aected. Furthermore, we generated mice containing a Y340FY341F knockin mutation of Raf-1 and showed that, while this mutated version of Raf-1 is not able to phosphorylate and activate MEK/ERK, the apoptosis phenotype of the raf-1 7/7 mice is not detected (HuÈ ser et al., 2001) .
To further investigate the in vivo role of A-Raf we have derived A-Raf de®cient mice and cell lines (Pritchard et al., 1996) . The A-raf gene is X chromosome linked and, therefore, through one targeting event in male embryonic stem (ES) cells, we were able to generate A-raf 7/Y ES cells. We have previously shown that male mice generated from these cells survive to birth but suer from progressive wasting, have a variety of postnatal neurological abnormalities, and eventually die 10 ± 21 days after birth (Pritchard et al., 1996) . In this report we have derived A-raf 7/Y MEFs and characterized these cells for their ability to proliferate, to undergo apoptosis, to activate the ERKs and to be transformed by Ras and Src oncogenes. The potential of A-raf 7/Y ES cells to form dierentiated tissues in teratomas was also tested. Our data show that A-Raf is not involved in mediating any of these cellular responses suggesting that this Raf isoform is not an important component of the Ras/ Raf/MEK/ERK cascade, at least in the cell types studied.
Results

Generation of A-Raf 7/Y ES cells and MEFs
Two independent A-Raf de®cient (A-raf 7/Y ) ES cell lines, clones 89 and 99, were generated by gene targeting of E14.1a ES cells with the pTCA ± Raf targeting vector as previously reported (Pritchard et al., 1996) . To obtain A-raf 7/Y MEFs and sibling control Araf +/Y MEFs, female A-raf +/7 mice on the C57BL6 genetic background were mated to C57BL6 wild-type males. Embryos were collected at E14.5 and ®broblasts were grown out from the embryos by standard procedures (Pritchard et al., 1996; HuÈ ser et al., 2001) . Genotypes of each cell line were con®rmed by PCR analysis of DNA obtained from each individual culture ( Figure 1a ). Western blot analysis with an anti-A-Raf antibody was used to con®rm that the ES cells and MEFs were indeed de®cient for the A-Raf protein and that no truncated protein products were expressed from the targeted gene (Figure 1b ; top panel). The Araf 7/Y MEFs and ES cells were normal in morphology compared to A-raf +/Y cells and showed no dierence in contact inhibited growth, cell adhesion, cell shape or motility (data not shown).
A-raf
7/Y cells do not show significant defects in cell proliferation or apoptosis The growth rates of the A-raf 7/Y primary MEFs were compared to the growth rates of the A-raf +/Y MEFs over 6 days in the culture. While some variation was observed between the growth rates of individual MEF cell lines, this did not re¯ect on the genotype of the MEF cell line (Figure 2a) Figure 3a ). ERK phosphorylation was also assessed in three other A-raf 7/Y MEF clones and in three other A-raf +/Y clones following EGF treatment for 10 min and a similar level of ERK phosphorylation was observed for clones of all genotypes (data not shown). ERK activation was also measured by performing an immunecomplex kinase assay using myelin basic protein (MBP) as a substrate for immunoprecipitated p42ERK. As with the ERK phosphorylation data, no dierence in ERK activity was observed between the A-raf +/Y and A-raf 7/Y cells following EGF treatment (Figure 3b ). In addition, no dierence in ERK activation was observed upon stimulation of the cells with platelet-derived growth factor or serum (data not shown).
No dierence in the level of expression of Raf-1 was observed in the A-raf ). Therefore, we analysed whether there were changes in Raf-1 and B-Raf activities in the Araf 7/Y cells by using the immunoprecipitation MEK/ ERK kinase cascade assay (Marais et al., 1997; HuÈ ser et al., 2001) . Since B-Raf is the most active Raf isotype in these assays in MEFs, we used the conditions optimized for the Raf-1 assay and decreased the sensitivity of the assay for B-Raf by using 10 times less protein lysate than for the Raf-1 assay (Materials and methods). Immortalized A-raf +/Y and A-raf 7/Y MEFs were made quiescent and stimulated with EGF over a time course of up to 10 min. Consistent with our previous observations, when stimulated with EGF, B-Raf activity in A-raf +/Y cells was increased by *1.5-fold and Raf-1 activity was increased by *2.4-fold (Figure 3d ). Both activities reached maximum stimulation at the 5 min time point and A-raf 7/Y cells were indistinguishable and exhibited a chaotic arrangement of various tissues including epithelium, cartilage, muscle and blood vessels ( Figure  4) .
Transformation of A-raf
7/Y and A-raf-1 +/Y MEFs by ras and src oncogenes
The ability of the A-raf 7/Y MEFs to be transformed by Ras and Src oncogenes was assessed. Primary MEFs were ®rst immortalized with the SV40 T antigen and permanent cell lines were derived (Materials and methods). Only cell lines with similar growth rates and expressing similar levels of the SV40 T antigen were analysed and compared in these experiments (data not shown). Three clones of each genotype were transfected with plasmid constructs expressing a transforming variant of Ha-ras or the chicken v-Src tyrosine kinase. Clones of each genotype expressing similar levels of v-Ha-Ras or v-Src were analysed ( Figure 5a ) and subjected to soft agar assays in order to assess their ability to undergo anchorage independent growth (Figure 5b and Table 1 ). The immortalized MEFs without a second oncogene were morphologically normal and had little ability to grow in soft agar ( Figure 5b and Table 1 ). In contrast, the oncogene transformed cells of both genotypes were highly refractile, were no longer contact inhibited and were able to grow in soft agar. The A-raf 7/Y MEFs showed no clear dierence in their ability to undergo Ha-ras or v-src induced anchorage independent growth compared to A-raf +/Y cells (Figure 5b ), although slightly more colonies were consistently obtained with the A-raf 7/Y clones than the A-raf +/Y clones transfected with oncogenic Ras.
Discussion
The A-raf gene was originally identi®ed by screening a mouse spleen cDNA library with a v-raf probe at low stringency (Huleihel et al., 1986) . The gene was subsequently mapped to the X chromosome and shown to have 70 ± 80% nucleotide sequence identity to raf-1. Compared to Raf-1 and B-Raf, relatively few biochemical studies have focussed on A-Raf function, despite the fact that this protein is expressed at high levels in many cell types (Luckett et al., 2000) . We have taken the approach of using gene knockout technology to further understand the function of A-Raf in intracellular signalling in vivo.
As with all Raf proteins, A-Raf has been shown to bind to Ras and MEK in vitro (Hagemann and Rapp, 1999) . However, in comparison to the other Raf proteins, the kinase domain of A-Raf has a much . Teratomas were ®xed, embedded in paran, sectioned and stained with haematoxylin and eosin. Scale bar represents 100 mm. M=muscle, BV=blood vessel, E=epithelia, C=cartilage weaker ability to phosphorylate and activate MEK/ ERK when over-expressed in tissue culture cells (Pritchard et al., 1995; Marais et al., 1997) . When expressed in Sf9 cells the kinase domain of B-Raf is over 500 times more ecient at phosphorylating MEK1 and MEK2 than the kinase domain of ARaf (Pritchard et al., 1995) . In addition, A-Raf immunoprecipitated from growth factor-stimulated MEFs cannot detectably activate MEK as measured by the kinase cascade assay (HuÈ ser et al., 2001) . The results presented in this report further support the view that A-Raf does not play a role in the Ras/Raf/ MEK/ERK cascade in vivo as there is no defect in ERK activation in A-raf 7/Y MEFs in response to growth stimulation (Figure 3a,b) . Since recent data also indicate that ERK activation by Raf-1 may have no physiological role (Mikula et al., 2001; HuÈ ser et al., 2001 ), B-Raf seems to be the main, if not the only, Raf isotype participating in the Ras/Raf/MEK/ ERK cascade in MEFs. The observation that ERK activation is signi®cantly disrupted in B-raf 7/7 MEFs is consistent with this conclusion (Wojnowski et al., 2000) . Data represent number of colonies obtained with 10 4 cells in assay. All assays were performed in triplicate and the mean value is given for each assay Previous investigations using over-expression in 3T3 cells have shown that Raf proteins can either induce cell cycle progression or cell cycle arrest depending on their level of activity towards the MEK/ERK pathway (Pritchard et al., 1995; Woods et al., 1997) . Low levels of Raf activity elicits cell cycle progression by inducing expression of cyclin D1 and cyclin E whereas high levels of Raf activity can induce the expression of p21
Cip1 which inhibits cell cycle progression (Pritchard et al., 1995; Woods et al., 1997) . Therefore, it was interesting to assess whether there were any defects in the cell cycle in MEFs and mice lacking A-Raf. The Araf 7/Y mice survive to birth and are normal in size at birth, suggesting that proliferation in embryogenesis is not signi®cantly disrupted. Consistent with this observation, we found no clear dierence in the ability of A-raf 7/Y MEFs to progress through the cell cycle compared to A-raf +/Y MEFs (Figure 2a,b) . Although the A-raf
7/Y mice demonstrate progressive wasting in the infant phase onwards, recent studies have shown that this is due to a feeding ataxia (C Pritchard and M Iwobi; unpublished data).
We also examined the ability of A-raf 7/Y MEFs to undergo programmed cell death (PCD) in response to a variety of apoptosis inducers compared to A-raf +/Y cells and observed no signi®cant dierence in PCD (Figure 2c ), unlike raf-1 7/7 cells which are more susceptible to PCD induced by etoposide and anti-CD95 antibody (HuÈ ser et al., 2001) . The A-raf 7/Y ES cells also showed no defect in their ability to dierentiate into multiple cell lineages in teratomas (Figure 4) , a result consistent with the observation that all tissues of the A-raf 7/Y mice develop normally (Pritchard et al., 1996) .
The A-raf 7/Y MEFs can be transformed eciently with the Src and Ha-Ras oncogenes ( Figure 5 and Table 1 ) and the ability of A-raf 7/Y ES cells to form teratomas is not disrupted. These results indicate that A-Raf is not important for the manifestation of the tumour phenotype. Previous studies using antisense or dominant inhibitory constructs in NIH3T3 cells showed the importance of Raf proteins for mediating the oncogenic eects of Ras and Src (Kolch et al., 1991; Qureshi et al., 1993) . Our data argue that A-Raf does not play a role in this process, indicating that Raf-1 or B-Raf are more important for oncogene transformation.
What then is the role of A-Raf? Our results have shown that A-Raf does not play a unique role in the Ras/Raf/MEK/ERK cascade or in mediating the downstream responses of this cascade, at least in MEFs. B-Raf activity is substantially elevated in the ARaf de®cient cells and Raf-1 activity to a lesser degree (Figure 3d ), suggesting that A-Raf may be involved in regulating the activities of these Raf isotypes. However, it is conceivable that the role of A-Raf as an ERK activator is highly tissue-speci®c and that the phenotype of the A-raf 7/Y mice can be explained by tissuespeci®c disruption of this pathway. The localization of A-Raf to mitochondria in rat liver (Yuryev et al., 2000) raises the distinct possibility that A-Raf has mitochondrial-speci®c functions that may include apoptosis. While we have shown that A-Raf is not involved in apoptosis in MEFs, this does not exclude the possibility that A-Raf has a tissue-speci®c apoptotic role. So far, we have not detected an increase in apoptosis in the liver or thymus of A-raf 7/Y animals.
Materials and methods
Derivation and genotyping of MEFs and ES cells
Two independent A-raf 7/Y ES cell lines (clones 89 and 99) were derived by undertaking one round of gene targeting with the pTCA-Raf knockout targeting vector in E14.1a ES cells as previously described (Pritchard et al., 1996) . Untargeted E14.1a ES cells represented A-raf +/Y controls. The A-raf primary MEFs were derived from E14.5 embryos arising from intercrosses between A-raf +/7 females maintained on the C57BL6 background and wild-type C57BL6 males. MEFs from individual embryos were derived by standard procedures (Pritchard et al., 1996; HuÈ ser et al., 2001) . PCR genotyping was performed with primers A (GGCGATGTAGCTGTGAAAGTG) and B (5'-GCTCA-GAGGAGAAAGGGTCA-3') for the wild-type allele, with primers C (CTTCCTGAGCACCTGCATCTC) and D (5'-CGTGCAATCCATCTTGTTCA) for the mutant allele and primers E (5'-GACTAGACATGTCTTAACATCTGTCC) and F (5'-CCTATTGCATGGACTGCAGCTTATG-3') for the Sry gene (Gubbay et al., 1992) . All PCR reactions were performed using Ready-To-Go PCR beads (Amersham Pharmacia Biotech Inc.) and primers at 1 pM/ml. PCR reactions were performed at 948C for 5 min followed by 35 cycles at 948C for 30 s, 608C for 30 s and 728C for 30 s. PCR products were electrophoresed on 1.2% (w/v) agarose gels. Primary cells were immortalized with the ZIPTEX virus expressing the SV40 large T-antigen (Sladek and Jacobberger, 1992) . Virus and cells were co-incubated in 8 mg/ml polybrene for 4 ± 24 h and immortalized cells were grown out by continuous culture.
Cell culture and plasmid transfections
ES cells were cultured in high glucose (4.5 g/l) Dulbecco's modi®ed Eagle's medium (DMEM; Life Technologies) containing 15% foetal calf serum (Life Technologies), 100 U/ml penicillin/streptomycin, 20 mM L-glutamine, 10 mM sodium pyruvate, non-essential amino acids, 115 mm b-mercaptoethanol and ESGRO Leukaemia Inhibitory Factor (LIF; Chemicon) on gelatin-treated plates. Primary and immortalized MEFs were cultured in low glucose DMEM (1 g/l) containing 10% foetal calf serum and 100 U/ml penicillin/streptomycin at 10% CO 2 in a humidi®ed incubator. Primary cultures were not passaged more than eight times. For growth factor stimulation, MEFs were made quiescent by culturing in DMEM containing 0.5% (v/v) FCS for at least 24 h. They were stimulated by addition of EGF (10 ng/ml) over a time course of up to 24 h. Oncogene plasmids, pZAS4ras and pZAS4src (supplied by M McMahon, University of California, San Francisco, USA), expressing the v-Ha-Ras and chicken v-Src oncogenes respectively and containing the Ecogpt selectable marker were transfected into A-raf 7/Y or A-raf +/Y MEFs by using lipofectamine according to the manufacturer's instructions (Life Technologies). Transfected cells were selected with medium containing hypoxanthine (15 mg/ml), aminopterin (2 mg/ml), thymidine (10 mg/ml), xanthine (250 mg/ml) and mycophenolic acid (25 mg/ml) and the resulting colonies were pooled.
Kinase assays and immunoblotting
Triton X-100 soluble protein lysates and Western blots were prepared as described previously (Marais et al., 1997; Luckett et al., 2000) . Primary antibodies used were: a 1 : 1000 dilution of an anti-p69
A7raf polyclonal antiserum (Santa Cruz Biotechnology), a 1 : 1000 dilution of the F9 vinculin monoclonal antibody (a gift from Dr V Koteliansky, CNRS, Paris), 1 : 2000 dilution of a mouse monoclonal antibody against Thr202/Tyr204 phospho-p44/42 ERK (New England Biolabs), a 1 : 1000 dilution of a rabbit polyclonal antibody against ERK2 (Zymed Laboratories Inc.), a 1 : 1000 dilution of an anti-avian Src mouse monoclonal antiserum against chicken v-Src (Clone EC10; Upstate Biotechnology, Inc.) and a 1 : 500 dilution of an anti-Ras mouse monoclonal antibody (Transduction Laboratories). Detection of the antigen ± antibody complexes was performed as described previously with the appropriate secondary antibody (Luckett et al., 2000) . Raf proteins were immunoprecipitated for 2 h at 48C from 0.1 ± 1 mg of cell extracts with 2 mg of the anti-Raf-1 antibody (Transduction Laboratories) or 4 mg of an anti-BRaf rabbit polyclonal antibody (Mason et al., 1999) . The activity of each Raf protein was assessed as described by Marais et al., 1997 . For B-Raf, 0.1 mg of lysate was used whereas for Raf-1, 1 mg of lysate was used. p42 ERK was immunoprecipitated by using 5 ml of a rabbit anti-p42ERK polyclonal antibody and ERK activity was measured using the MBP kinase assay (Samuels et al., 1993) .
Proliferation and apoptosis analysis
For growth curves, 2610 4 primary cells were plated per well of a 24-or 12-well plate. Cells were counted at 24 h intervals in triplicate using a haemocytometer. For DNA synthesis assays the method described by Treinies et al. (1999) and HuÈ ser et al. (2001) was followed. To induce apoptosis, primary cells at 80% con¯uency on 6 cm dishes were treated with etoposide (50 mm), anti-CD95 antibody (50 ng/ml) with 0.5 mm cycloheximide or serum-free medium for 20 h in a 378C humidifying incubator. Annexin V staining and FACS analysis were performed as described in HuÈ ser et al. (2001) . Data were analysed by using the unpaired 2-tailed independent t-test to assess the signi®cance of the results.
Transformation assays
For soft agar assays, cells were trypsinized and counted using a haemocytometer. 10 3 , 10 4 and 10 5 cells were then placed in medium containing 0.35% (w/v) low-melting-temperature agarose. For the Ras and Src transformed cells HAT selection was also included in the medium. After 21 days, cells were stained with MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide). The stained plates were photographed and the colonies were counted using a Gel Doc 2000 system (BioRad) and Quantity One software with the sensitivity level set at 3.0.
Teratoma formation
ES cells were cultured, trypsinized, washed with PBS and 5610 6 cells in PBS were injected subcutaneously into thē ank of 8-week-old syngeneic 129Ola male mice. After 3 weeks, tumours were collected, weighed, ®xed in 4% (w/v) paraformaldehyde, embedded in paran and 5 mm sections were prepared and stained with haematoxylin and eosin. Sections were analysed under a Leica DMLB light microscope.
